JERUSALEM, June 6 /CNW/ -- Oramed Pharmaceuticals, Inc. (OTC Bulletin
Board: ORMP ; FTSE: OJU) invites everybody to join Nadav Kidron on
www.ceocast.com to discuss the future of Oramed Pharmaceuticals Inc., and
update the investment community on the present status of the company. The
interview will take place at 3pm Eastern time on Thursday, June 7. If you have
any specific questions to ask, please email them to email@example.com for
the interviewer to ask on Thursday morning.
To hear the interview in its entirety, please visit http://
www.ceocast.com/. Please click on the company name to the left of the site, or
look for Oramed in the archives at a later date.
CEO Nadav Kidron stated, "We have had a steady progress over the past 2
months and are looking forward to speaking with our supportive shareholders."
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals Inc. is an Israeli company focused on the
development of oral delivery solutions based on proprietary technology.
Diabetes is one of the most rapidly growing diseases in the world and is one
that requires constant and often unpleasant monitoring and drug therapy
regimen. Oramed is currently developing an orally ingestible soft gel insulin
capsule for the treatment of diabetes. The Company is also pursuing the
development of oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website
Legal Notice Regarding Forward Looking Statements
This news release contains statements, which may constitute
"forward-looking statements". Those statements include statements regarding
the intent, belief or current expectations of Oramed as well as the
assumptions on which such statements are based. Forward-looking statements in
this release include: that we are currently developing an orally soft gel
insulin capsule for the treatment of diabetes; and that we are also pursuing
the development of oral delivery solutions for other drugs and vaccines.
Factors which may significantly change or prevent our forward looking
statements from fruition include that we may be unsuccessful in developing any
products; we may be unable to raise funds and resources to pursue research and
development; we may be unable to successfully defend our patents from
infringement by third parties, there is a risk that our patents may be
subsequently shown to be invalid or infringe the patents of others; we may be
unable to attract or retain our key employees, consultants and advisors, our
products may never gain FDA or other regulatory body approval for human
consumption and we may be unable to successfully commercialize our future
products. Readers should refer to our most recent 10-KSB filed on Edgar and
the 8-K announcing our acquisition of the Oramed technology filed March 8,
For further information:
For further information: Investor Relations Contact: Vinisha Agnihotri
for Oramed Pharmaceuticals, Inc., +1-646-467-2252, firstname.lastname@example.org Web
Site: http://www.ceocast.com http://www.oramedpharma.com